Two Editorial Board Members of Journal of Cancer Metastasis and Treatment Named to the List of Clarivate 2022 Highly Cited Researchers
The annual list of the world's Highly Cited Researches was released on November 15, 2022. The Editorial Office of Journal of Cancer Metastasis and Treatment is proud to announce that Associate Editor Prof. Jesús F. San-Miguel and Editorial Board member Prof. Giuseppe Curigliano have been named to the Highly Cited Researchers 2022 list by Clarivate. Sincere congratulations to the researchers!
Clarivate Plc, a leader in providing trusted information and insights to accelerate the pace of innovation, awarded the designations to 6,938 researchers from around the world who demonstrated significant influence in their chosen fields over the last decade. The Highly Cited Researchers' names are drawn from the highly cited papers that rank in the top 1% by citations for field and publication year in the Web of Science™ citation index over the past decade.
Prof. Jesús San-Miguel
Highly Cited Researcher in the field of Clinical Medicine- 2022
University of Navarra, Center of Investigation Applied Medical, IDISNA, CIBERONC, Pamplona, Spain.
Jesús San-Miguel, MD, PhD, Professor of Hematology (Chair) and Medical Director at the University of Navarra, Director of Translational Medicine at Cima Universidad of Navarra, and Director of Clinical and Translational Medicine at the University of Navarra, Center of Investigation Applied Medical, IDISNA, CIBERONC, Pamplona, Spain. He has participated in more than 160 communications at national and international conferences. He has contributed to 120 chapters and monographs. He has also contributed to more than 830 articles in international and 141 national journals. He has participated in 50 national, 5 European and 2 American research projects and conducted more than 35 clinical trials as a principal investigator.
Prof San-Miguel has received numerous awards, including the Waldenstöm Award, EBMT Lecture, Kyle Lifetime Achievement Award, Jose Carreras EHA Award, Ham-Wasserman Lecture Award, Rey Jaime I Award in Clinical Medicine, and the Spanish Prizes in both oncology and translational research.
Prof. Giuseppe Curigliano
Highly Cited Researcher in the field of Clinical Medicine- 2022
Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy.
Giuseppe Curigliano is Associate Professor of Medical Oncology at the University of Milano and the Head of the Division of Early Drug Development at the European Institute of Oncology, IRCCS, Italy. He is a clinician and researcher specializing in early drug development and target oriented therapies for patients with solid tumours with a special commitment to breast cancer. He has been a member of the Italian National Health Council since 2018 and, in 2019, he served as Chair of the Scientific Committee of The Lega Nazionale Lotta ai Tumori. Prof. Curigliano has also served as a Member of the ESMO Breast Cancer Faculty since 2001 and he is currently the Faculty Coordinator. He has also served on the Scientific Committee for the St Gallen Conference since 2011, and was the Scientific Co-Chair in St Gallen 2017 and 2019. He also serves on the European School of Oncology (ESO) faculty committee. Giuseppe Curigliano was awarded the first ESO Umberto Veronesi Award in Vienna in 2017 and with the Fellowship of the European Academy of Cancer Sciences in Paris in 2017.
We welcome more international outstanding researchers with academic and publishing enthusiasm to join the Editorial Board of JCMT to advance the development of cancer research and metastasis.
The full list of Clarivate's Highly Cited Researchers 2022 can be found here.
Respectfully submitted by Paula Sun, the Science Editor of Journal of Cancer Metastasis and Treatment
